Pa Shun International Holdings (0574) Fair Value & Analysis
Healthcare · HK · Market cap HK$35.8M
Fair value as of: Aug 13, 2026
From 5 valuation models · updated 2 days ago
Below-average quality, currently priced close to our fair value.
What matters now
- The price is below even our cautious bear case (HK$0.0184). The market is more pessimistic than our downside scenario.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- The models converge in a tight band (HK$0.0184 to HK$0.0202), unusually little disagreement for a valuation.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.0180 – HK$0.0698 · fair‑value band HK$0.0184 – HK$0.0202 · the HK$0.0180 price screens below the HK$0.0184 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Pa Shun International Holdings (0574) currently trades at HK$0.0180, while our model-based Fair Value estimate is HK$0.0184, implying the stock looks roughly 2.2% fairly valued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Pa Shun International Holdings generated revenue of HK$86.8M at a net margin of -18.3%. Revenue grew 1.0% year over year. It earns a return on equity of -22.0%. Net debt stands at HK$40.0M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.0184 (bear case) to HK$0.0202 (bull case); at HK$0.0180, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 76% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 2%, 0574 screens cheaper than that median.
Notify me when 0574 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas. It also sells pharmaceutical products manufactured by the company.
Full company description
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas. It also sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. Pa Shun International Holdings Limited was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Pa Shun International Holdings Limited operates as a subsidiary of Praise Treasure Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pa Shun International Holdings reported revenue of HK$86.8M in FY2025 versus HK$86.4M in FY2021, a compound +0.1%/yr. Reported net income was −HK$15.9M in FY2025.
Watch 0574: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 62 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.33 | HK$2.04 | -39% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| MedPlus Health Services Limited MEDPLUS | ₹675.05 | ₹379.25 | -44% |
| Yixintang Pharmaceutical Group 002727 | ¥12.29 | ¥9.45 | -23% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.51 | ¥10.05 | -39% |
Compare Pa Shun International Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pa Shun International Holdings (0574) overvalued or undervalued?
What is the fair value of 0574?
What is the quality score of 0574?
What is the revenue of Pa Shun International Holdings (0574)?
What is the net profit margin of 0574?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pa Shun International Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.